Ann: Companion Diagnostic Study Initiated with UON, page-63

In my mind this is further evidence that "the market" is placing a very low value on Pillar One - FTO.

Double zero and you get zero, which is approximately the price movement today!

IMHO you'd be hard pressed to find a more enduring ASX investment opportunity than this years' sideways consolidation of RAC. Multiple independent papers come out each month deepening and broadening the FTO application, pre-clinical and now clinical research progresses to de-risk the application across the 3-Pillars (some of this work is internal while some of it, such as the research that suggested the MDS trial, is from independent parties), and all this time the share price sits there tracing out wedges as the TA plays out while the FA drops multiple news updates, some of which has, IMO, non-trivial probability of doubling the value of Zantrene!